Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | GALK1 | P51570 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865333 | 0.85 | TRPV1 (0.56) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4023574 | 0.83 | MAPT (0.62) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5660097 | 0.83 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL3246360 | 0.82 | TRPV1 (0.63) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30114438 | 0.81 | TRPV1 (0.64) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4023786 | 0.81 | TRPV1 (0.64) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12862996 | 0.81 | KDM4E (0.62) | MAPTALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL4028212 | 0.81 | TRPV1 (0.65) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30544195 | 0.80 | KDM4E (0.67) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2315592 | 0.80 | KDM4E (0.67) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | TRPV1 2943/4885MAPT 2802/4885LMNA 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.